May 8 (UPI) -- The Food and Drug Administration on Thursday announced what it called an aggressive agency-wide artificial intelligence adoption timeline, as well as a new AI tool to help scientists spend less time on tedious, repetitive tasks that can slow the review process. The FDA made the announcement in statement about " an aggressive timeline to scale use of artificial intelligence internally across all FDA centers by June 30, 2025, following the completion of a new generative AI pilot